Thrombosis in paroxysmal nocturnal hemoglobinuria
Top Cited Papers
- 20 June 2013
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 121 (25), 4985-4996
- https://doi.org/10.1182/blood-2012-09-311381
Abstract
The most frequent and feared complication of paroxysmal nocturnal hemoglobinuria (PNH) is thrombosis. Recent research has demonstrated that the complement and coagulation systems are closely integrated with each influencing the activity of the other to the extent that thrombin itself has recently been shown to activate the alternative pathway of complement. This may explain some of the complexity of the thrombosis in PNH. In this review, the recent changes in our understanding of the pathophysiology of thrombosis in PNH, as well as the treatment of thrombosis, will be discussed. Mechanisms explored include platelet activation, toxicity of free hemoglobin, nitric oxide depletion, absence of other glycosylphosphatidylinositol-linked proteins such as urokinase-type plasminogen activator receptor and endothelial dysfunction. Complement inhibition with eculizumab has a dramatic effect in PNH and has a major impact in the prevention of thrombosis as well as its management in this disease.This publication has 136 references indexed in Scilit:
- Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuriaHaematologica, 2011
- The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis modelBlood, 2010
- Complement activation on platelets: Implications for vascular inflammation and thrombosisMolecular Immunology, 2010
- Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinuxLeukemia Research, 2010
- Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabHaematologica, 2010
- Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In VivoCell, 2009
- Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodiesLupus, 2009
- Complement activation triggered by chondroitin sulfate released by thrombin receptor‐activated plateletsJournal of Thrombosis and Haemostasis, 2008
- Expression of tissue factor pathway inhibitor by endothelial cells and plateletsTransfusion and Apheresis Science, 2008
- Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2004